|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-05
|
$666,396
|
$666,396
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
$76,950
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
$135,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
$109,294
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-05
|
$826,500
|
$206,625
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
Pediatric Oncology Clinical Research Training Program
|
5K12CA090433-17
|
$827,164
|
$827,164
|
BLANEY, SUSAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Functional Genomics and Precision Therapy Testing for Langerhans Cell Histiocytosis
|
1F31CA228360-01
|
$44,524
|
$44,524
|
BURKE, THOMAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-04
|
$119,807
|
$119,807
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
$252,758
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cognitive Change after Proton RT vs. Photon or Surgery for Pediatric Brain Tumor
|
5R01CA187202-05
|
$577,030
|
$577,030
|
KAHALLEY, LISA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
5R01CA207086-02
|
$370,641
|
$370,641
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
$7,156
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
$45,800
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
5R01CA215452-02
|
$362,569
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
$249,638
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-04
|
$462,191
|
$115,548
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$11,888
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$25,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$12,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$320,312
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-05
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
5R03CA215940-02
|
$75,288
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-04
|
$604,525
|
$604,525
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
$124,500
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-07
|
$369,725
|
$369,725
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
5R01CA214965-03
|
$444,571
|
$444,571
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
$98,089
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
7R01CA211614-02
|
$475,560
|
$237,780
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
$23,843
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
5R01CA213131-02
|
$430,377
|
$107,594
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
5R01CA157644-09
|
$410,875
|
$410,875
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
$1,035,561
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
3R21CA205106-02S1
|
$77,331
|
$77,331
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
5R21CA205106-02
|
$176,605
|
$176,605
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$203,455
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$69,200
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$3,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
5K08CA201591-02
|
$169,560
|
$42,390
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5R00CA188595-04
|
$249,000
|
$37,350
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms of regulation by RNA in acute myeloid leukemia
|
5R35CA197697-04
|
$1,042,185
|
$260,546
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Enhancer RNA-mediated Tumor Suppressor Gene Expression in Normal and Malignant Hematopoiesis
|
5K01CA222707-02
|
$114,242
|
$28,561
|
TRINH, BON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
$348,768
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
5R44CA213595-02
|
$712,071
|
$178,018
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
5R01CA204231-02
|
$390,712
|
$195,356
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
5R01CA196703-04
|
$404,888
|
$404,888
|
CHIARLE, ROBERTO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
Total relevant funding to Childhood Cancers for this search: $302,325,670
|